BC Week In Review | Apr 27, 2018
Company News

Orexigen accepts $75M stalking horse bid

On April 23, Orexigen Therapeutics Inc. (NASDAQ:OREX) accepted a $75 million cash bid from an investor group including Pernix Therapeutics Holdings Inc. (NASDAQ:PTX) to acquire Orexigen assets including worldwide rights to obesity drug Contrave naltrexone/bupropion....
BC Week In Review | Mar 16, 2018
Financial News

Orexigen files for bankruptcy

Orexigen Therapeutics Inc. (NASDAQ:OREX) said on March 12 it filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware and plans to pursue an auction sale of substantially all of...
BC Innovations | Sep 21, 2017
Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co ., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race...
BC Week In Review | Sep 5, 2016
Company News

Orexigen, Valeant Pharmaceuticals deal

Orexigen’s Orexigen Therapeutics Ireland Ltd. subsidiary granted Valeant’s Valeant Canada L.P. subsidiary exclusive rights to develop and commercialize obesity drug Contrave naltrexone/bupropion in Canada. Valeant said it plans to submit an NDA in Canada by...
BioCentury | May 30, 2016
Strategy

Taking Takeda global

Two years after joining Takeda Pharmaceutical Co. Ltd. , Christophe Weber has narrowed the company's therapeutic focus, expanded the executive team and reorganized its approach to market with the aim of transforming the company into a...
BC Week In Review | Apr 25, 2016
Clinical News

Contrave: Phase IV discontinued

Orexigen discontinued the double-blind, placebo-controlled Phase IV CONVENE trial of Contrave following termination of a 2010 deal that granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Osaka, Japan) U.S. rights to the product (see BioCentury, March 16)....
BioCentury | Mar 21, 2016
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 3/18 cls Epizyme Inc. (NASDAQ:EPZM) H.C. Wainwright Andrew Fein Upgrade Buy (from neutral) 6% $10.96 Fein also raised his target...
BC Week In Review | Mar 21, 2016
Company News

Orexigen, Takeda deal

Orexigen and Takeda terminated the U.S. portion of a 2010 deal granting Takeda exclusive rights to commercialize obesity drug Contrave naltrexone/bupropion in North America. Orexigen regained Canadian and Mexican rights last year. The U.S. transaction...
BC Week In Review | Mar 21, 2016
Company News

Orexigen, Valeant Pharmaceuticals deal

Orexigen’s Orexigen Therapeutics Ireland Ltd. subsidiary granted Valeant’s Valeant Holdings Ireland subsidiary rights to obesity drug Mysimba naltrexone/bupropion in 19 countries in and around Europe. The deal covers Greece, Slovenia, Slovakia, Czech Republic, Hungary, Croatia,...
BC Extra | Mar 16, 2016
Company News

Orexigen gets back U.S. Contrave rights

Orexigen Therapeutics Inc. (NASDAQ:OREX) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) are ending their deal under which Takeda was commercializing obesity drug Contrave naltrexone / bupropion in the U.S. Separately on Tuesday, Orexigen said it granted...
Items per page:
1 - 10 of 280